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Voltage-gated Na (NaV) channels are key regulators of myo-
cardial excitability, and Ca2/calmodulin-dependent protein
kinase II (CaMKII)-dependent alterations in NaV1.5 channel
inactivation are emerging as a critical determinant of arrhyth-
mias in heart failure. However, the global native phosphoryla-
tion pattern of NaV1.5 subunits associated with these arrhyth-
mogenic disorders and the associated channel regulatory defects
remain unknown. Here, we undertook phosphoproteomic anal-
yses to identify and quantify in situ the phosphorylation sites
in the NaV1.5 proteins purified from adult WT and failing
CaMKIIc-overexpressing (CaMKIIc-Tg) mouse ventricles. Of
19 native NaV1.5 phosphorylation sites identified, two C-
terminal phosphoserines at positions 1938 and 1989 showed
increased phosphorylation in the CaMKIIc-Tg compared with
theWTventricles.Wethen tested thehypothesis thatphosphor-
ylation at these two sites impairs fibroblast growth factor 13
(FGF13)-dependent regulation of NaV1.5 channel inactivation.
Whole-cell voltage-clamp analyses in HEK293 cells demon-
strated that FGF13 increases NaV1.5 channel availability and
decreases late Na current, two effects that were abrogated
with NaV1.5 mutants mimicking phosphorylation at both sites.
Additional co-immunoprecipitation experiments revealed that
FGF13 potentiates the binding of calmodulin toNaV1.5 and that
phosphomimetic mutations at both sites decrease the interac-
tion of FGF13 and, consequently, of calmodulin with NaV1.5.
Together, we have identified two novel native phosphoryla-
tion sites in the C terminus of NaV1.5 that impair FGF13-de-
pendent regulation of channel inactivation and may contrib-
ute to CaMKIIc-dependent arrhythmogenic disorders in
failing hearts.
Voltage-gated Na (NaV) channels are critical determinants
ofmyocardial excitability, and defects inNaV channel function-
ing or regulation in the context of inherited or acquired cardiac
disease increase the risk of life-threatening arrhythmias (1).
Under physiological conditions, the primary ventricular NaV
channel subunits, the NaV1.5 channels, activate and inactivate
rapidly to generate the transient peakNa current, INa, respon-
sible for the depolarization phase and the propagation of action
potentials. However, a small proportion of NaV channels inac-
tivates slowly to generate a late or persistent Na current,
referred to as INaL, contributing markedly to determining
action potential waveform, duration, and refractoriness. Among
the various determinants recognized to causeNaV channel dys-
functions and consequent increased risk of acquired arrhyth-
mias is the activation of Ca2/calmodulin-dependent protein
kinase II (CaMKII)3 (2–7). A prime example of this dysregula-
tion is heart failure in which an increased INaL has been linked
to the activation of CaMKII (2, 4–7) and associated alteration
in NaV1.5 phosphorylation (7). This increased INaL in failing
hearts is sometimes accompanied by a decreased NaV channel
availability caused by a hyperpolarizing shift of the voltage
dependence of steady-state INa inactivation (2, 7). Three phos-
phorylation sites in the first linker loop of NaV1.5, at positions
516 (8, 9), 571 (10–12), and 594 (8), have been suggested to play
causative roles in these deleterious CaMKII-dependent
mechanisms. Nonetheless, the global native phosphorylation
pattern of NaV1.5 channels associated with CaMKII activation
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in failing hearts as well as themolecularmechanisms associated
with altered phosphorylation that underlie the defects in chan-
nel inactivation remain unknown.
The understanding of NaV1.5 channel inactivation has
received much attention over the past decade and has recently
been buttressed by the generation of several crystal structures
of the cytoplasmicC-terminal domain (CTD) ofNaV1.5 (as well
as of other NaV subunits) in complex with Ca2-free or Ca2-
bound calmodulin (CaM) and/or a member of the intracellular
fibroblast growth factor (iFGF) family of proteins (13–16). The
Ca2-binding protein CaM acts as a sensor for Ca2 and regu-
lates inactivation of NaV channels, while underlying mecha-
nisms still elude consensus. Depending on whether CaM is
loaded with Ca2, it binds different sites within and around the
IQ motif in the CTD and/or the third linker loop of NaV chan-
nels, thereby inducing conformational changes and affecting
channel inactivation and the late Na current (13–19). iFGFs,
which include FGF11–14, are also constitutive NaV channel-
associated proteins, binding the CTD of NaV channels, just
upstream of the IQmotif (14–16, 20–22). Themost consistent
effect of iFGFs is to increase the availability of NaV channels by
shifting the voltage dependence of steady-state inactivation
toward depolarized potentials (15, 20–26). The central role of
the NaV1.5 CTD as well as of iFGFs and CaM in regulating the
inactivation properties of NaV1.5 channels is highlighted by the
effects of several mutations observed in the arrhythmic long
QT3 (LQT3) and Brugada syndromes thatmap to their binding
interfaces (14, 27–29).
This study uses a mass spectrometry (MS)-based phospho-
proteomic analysis to identify and quantify in situ the native
phosphorylation sites in the NaV1.5 proteins purified from fail-
ing CaMKIIc-overexpressing (CaMKIIc-Tg) versus non-fail-
ing wild-type (WT) mouse ventricles. The rationale for using
this transgenic and failing mouse model is to identify the
NaV1.5 phosphorylation sites that participate in the channel
inactivation defects associated with the activation of CaMKIIc
in heart failure. Further biochemical and electrophysiological
approaches in human embryonic kidney 293 (HEK293) cells
were then used to investigate the impact of phosphorylation at
twoC-terminal serine residues on the interaction of FGF13 and
CaM with NaV1.5 and on the inactivation properties of NaV1.5
channels.
Results
Purification and characterization of NaV channel complexes
fromWT and CaMKIIc-Tgmouse ventricles
Total lysates from four adultWTand fourCaMKIIc-Tg (30)
mouse (m) ventricles were prepared, pooled, and used in eight
distinct IPs (fourWT IPs and four CaMKIIc-Tg IPs) using the
mNaVPAN-specific antibody. As illustrated in Fig. 1A and
consistent with previous findings (7), Western blot analyses of
total lysates showed greater NaV1.5 protein expression in the
CaMKIIc-Tg compared with the WT ventricles. This differ-
ence in total protein expression resulted in significantly (p 
0.05) higher NaV1.5 protein abundance (3.8-fold) in the
mNaVPAN-IPs from the CaMKIIc-Tg than from the WT
ventricles (Fig. 1, A and B). Accordingly, analyses of mNaVPAN-
IPs on SYPRO Ruby-stained gels revealed the presence of a
band corresponding to the molecular weight of NaV  subunits
(31), the intensities of which are higher in the CaMKIIc-Tg IPs
than in the WT IPs (Fig. 1C).
The protein components of isolated NaV channel complexes
from WT and CaMKIIc-Tg ventricles were identified by MS
using three distinct mass spectrometers: an LTQ-Orbitrap XL,
an LTQ-Orbitrap Elite, and aTripleTOF5600 Plus. TheNaV1.5
protein was the most abundant protein in the mNaVPAN-IPs
from bothWT and CaMKIIc-Tg ventricles with average num-
bers of total exclusiveMS/MS spectra acquired increasing from
95 using the Orbitrap XL to 177 using the Orbitrap Elite and
524 using the TripleTOF (Fig. 2A). These greater sensitivities of
the Orbitrap Elite and TripleTOF mass spectrometers improved
Figure 1. Immunoprecipitation of NaV channel complexes from adult WT and CaMKIIc-Tg mouse ventricles. A, representative NaV  Western blots
of total lysates and immunoprecipitated proteins from adult WT and CaMKIIc-Tg mouse ventricles with the anti-NaVPANmonoclonal antibody (mNaVPAN-
IPs) probed with the anti-NaV1.5 rabbit polyclonal (RbNaV1.5) and the mNaVPAN antibodies, respectively. B,mean S.E. relative NaV  protein abundance
in WT (n  4) and CaMKIIc-Tg (n  4) IPs. *, p  0.05, Mann-Whitney test. C, SYPRO Ruby-stained gel of mNaVPAN-IPs from WT and CaMKIIc-Tg mouse
ventricles. Relative abundance of proteins running at the molecular weight of NaV  subunits is higher in CaMKIIc-Tg IPs than in WT IPs.
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Figure 2. MS protein identification in immunoprecipitated NaV channel complexes from WT and CaMKIIc-Tg mouse ventricles. A, NaV  subunits
identified using the LTQ-Orbitrap XL, LTQ-Orbitrap Elite, and TripleTOF 5600 Plusmass spectrometers. The average numbers of exclusive unique peptides and
total spectra for eachNaV subunit and thepercent aminoacid sequence coveragesobtained forNaV1.5, includingor excluding transmembranedomains (TD),
are presented. In addition to NaV1.5, which is the most abundant protein in the mNaVPAN-IPs, NaV1.4 is also detected, and the greater sensitivity of the
Orbitrap Elite and TripleTOF mass spectrometers allowed the identification of NaV1.7, NaV1.8, and NaV1.3. B, amino acid sequence coverage obtained for the
(mouse) NaV1.5 protein (NP_001240789). Detected peptides are highlighted in yellow; identified phosphorylation sites are highlighted in blue (sites already
identified in our previousMS analyses) and red (newly identified sites in the present study); transmembrane segments (S1–S6) in each domain (I–IV) are in bold
and underlined in black; loops I, II, and III correspond to interdomains I and II, II and III, and III and IV, respectively; and binding sites for iFGF and calmodulin
(IQ-motif) are boxed in green and orange, respectively. C, relative abundances of NaV  subunits and previously characterized NaV1.5 channel-associated/
regulatory proteins in the CaMKIIc-Tg IPs (n 4) versus theWT IPs (n 4) were calculated from the entire (Orbitrap XL)MS1 peptide data set using the DAnTE
statistical software (**, p 0.01; ***, p 0.001).
Phosphorylation and inactivation of cardiac NaV1.5 channels
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the NaV1.5 amino acid sequence coverage from 27 to 28 and
32%, respectively, and from 36 to 38 and 43% with the trans-
membrane domains removed. NaV1.4 was the second most
abundant NaV  subunit with much fewer spectra acquired: 5,
7, and 30 using theOrbitrapXL,Orbitrap Elite, andTripleTOF,
respectively. Most interestingly, the greater sensitivity of the
TripleTOF mass spectrometer allowed the identification of
three additional NaV  subunits, NaV1.7 (four spectra), NaV1.3
(three spectra), and NaV1.8 (two spectra). These experiments
also led to the reliable identification of several previously iden-
tified NaV1.5 channel-associated/regulatory proteins (32),
including the ,, and  subunits of CaMKII, CaM, FGF13, and
ankyrin-G (Fig. 2C). The supplemental Tables 1–3 provide the
complete lists of identified peptides and proteins using the
Orbitrap XL, Elite, and the TripleTOF mass spectrometers,
respectively.
The relative abundances of identified proteins in the mNaV
PAN-IPs from the CaMKIIc-Tg versus theWT ventricles were
calculated from the MS1 peptide data (Orbitrap XL) using the
DAnTE statistical analysis tool (33–35). Consistent with the
biochemistry data (Fig. 1), the NaV1.5 protein is 2.9-fold (p 
0.001) more represented in the CaMKIIc-Tg IPs than in the
WT IPs (Fig. 2C). Interestingly, this quantitative MS analysis
also revealed that of the 10 NaV1.5-associated/regulatory pro-
teins identified, the abundance ratios of CaMKII, 2-syntro-
phin, and dystrophin in the CaMKIIc-Tg versus the WT IPs
are substantially greater than the 2.9-fold abundance ratio
obtained for NaV1.5. On the contrary, the CaMKII and  sub-
units as well as CaM and FGF13 are relatively less represented
compared with NaV1.5. The abundance ratios obtained for
ankyrin-G, plakophilin-2, and 1-syntrophin are close to the
NaV1.5 abundance ratio. Taken together, these observations
demonstrate that NaV1.5 is more expressed in the CaMKIIc-
Tg than in the WTmouse ventricles, which, as a consequence,
led to greater NaV1.5 IP yields from the CaMKIIc-Tg than
from the WT ventricles. These analyses also suggest different
relative compositions of associated/regulatory proteins in
NaV1.5 channel complexes in theCaMKIIc-Tg comparedwith
the WT ventricles.
Identification of native NaV1.5 phosphorylation sites fromWT
and CaMKIIc-Tgmouse ventricles
To determine the global native phosphorylation pattern
of NaV1.5 channels associated with the overexpression of
CaMKIIc, a quantitative phosphoproteomic analysis of the
NaV1.5 proteins purified from the CaMKIIc-Tg and the WT
mouse ventricleswas performed. This phosphoproteomic anal-
ysis unambiguously allowed the identificationof 19nativephos-
phorylation sites in themouse ventricular NaV1.5 protein (Figs.
2B and 3). Table 1 lists the phosphopeptides enabling the best
phosphorylation site assignment(s), with the mass spectrome-
ter used for the identification and the percentages of maximum
intensities of site-discriminating ions, for each phosphorylation
site. Representative MS/MS (and MS1) phosphopeptide spec-
tra are presented in supplemental Fig. 1. Descriptions of all
detected site-discriminating and supporting ions (calculated
mass errors, confirmations of charge states) are given in sup-
plemental Tables 4. Among the 19 NaV1.5 phosphoserines
(pSer) or phosphothreonines (pThr) identified, 10 (in blue) had
already been identified in our previous phosphoproteomic
analyses (31) and nine (in red) are novel (Figs. 2B and 3). These
nine novel phosphorylation sites are located in the first (pThr-
486, pSer-499, pSer-516, and pSer-539) and second (pSer-1012)
intracellular linker loops as well as in the CTD (pSer-1888,
pSer-1937, pSer-1938, and pSer-1989) of NaV1.5. Interestingly,
the three C-terminal pSer-1888, pSer-1937, and pSer-1938 are
in close proximity to the binding sites for the iFGFs (14–16,
20–22) and CaM (IQ-motif) (13–19).
To determine whether one or several of these MS-identified
NaV1.5 phosphorylation sites are associated with the overex-
pression of CaMKIIc, the relative abundance of each NaV1.5
phosphopeptide in theCaMKIIc-Tg versus theWTmNaVPAN-
IPs was determined by label-free quantification of MS1 data
(36). As illustrated in Fig. 4A, and consistent with the quantifi-
cation of the biochemical (Fig. 1) and the MS protein (Fig. 2C)
data, the unphosphorylated NaV1.5 peptides are 3.6-fold more
represented in the CaMKIIc-Tg versus the WT IPs. Of the 86
unphosphorylated and 32 phosphorylated NaV1.5 peptides
Figure3. LocalizationofMS-identified in situphosphorylation siteson themouseventricularNaV1.5 subunitprotein.Among the19phosphorylation
sites identified, 10 (in blue) had already been identified in our previous MS analyses and 9 (in red) are novel. Four and two phosphorylation site locations are
possible at amino acids 36–42 and 524–525, respectively. The three newly identified C-terminal phosphoserines at positions 1888, 1937, and 1938 (pSer-1888,
pSer-1937, and pSer-1938) are in close proximity to the binding sites for iFGF and calmodulin (IQ-motif).
Phosphorylation and inactivation of cardiac NaV1.5 channels
17434 J. Biol. Chem. (2017) 292(42) 17431–17448
 at W
ashington U
niversity on January 17, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(118 peptides total), only the three phosphopeptides AT(pS)
DNLPVR, RL(pS)(pS)GTEDGGDDR, and AL(pS)AVSVLT-
SALEELEESHRK (marked with a † in Fig. 4A), exhibiting
phosphorylation(s) on serines 1989 (pSer-1989), 483 and 484
(pSer-483 and pSer-484), and 664 (pSer-664), respectively,
present fold change ratios (8.96-, 7.13-, and 0.58-fold) signifi-
cantly different from the median ratio (Tukey whisker analysis,
Fig. 4B). Nonetheless, the other phosphopeptides assigning
pSer-483 and/or pSer-484 do not show any significant abun-
dance changes compared with the median ratio (Fig. 4, A and
B); and the abundance change observed for the phosphopeptide
identifying pSer-664 is not significantly different between the
mNaVPAN-IPs from theCaMKIIc-Tg and theWTventricles
(Fig. 4A). In addition, the phosphopeptide Q(17.03)QAGSS-
GLSDEDAPER, assigning pSer-1937 and/or pSer-1938 (Table
1), is present in the CaMKIIc-Tg IPs (n  3/4) and absent in
the WT IPs (n  0/4) (Fig. 4C). Relative abundances of all
the other NaV1.5 phosphopeptides are comparable with the
median (or mean) relative abundance found for the unphos-
phorylated NaV1.5 peptides (Fig. 4, A and B).
Amino acid sequence alignment of the flanking regions of
pSer-1937/38 and pSer-1989 showed a good conservation of
Ser-1938 and Ser-1989 across orthologous sequences (Ser-1937
is notwell-conserved) and, interestingly, revealed that Ser-1989
conforms to the consensus CaMKII phosphorylation site
(RXX(S/T) Fig. 4D (37)). Taken together, these phosphopro-
teomic analyses identified nine novel native NaV1.5 phosphor-
ylation sites, of which two conserved serines in the CTD, at
Table 1
Phosphorylation sites, phosphopeptides, and site-discriminating ions identified in immunoprecipitated NaV1.5  subunits from adult WT
and/or CaMKIIc-Tg mouse ventricles using MS
The site-discriminating ions observed in the high-resolution (LTQ-Orbitrap Elite or TripleTOF 5600 Plus) or low-resolution (LTQ-Orbitrap XL) MS/MS spectra of each
annotatedNaV1.5 phosphopeptide support the assignment of the indicated phosphorylation site(s). The charge state as well as the percentage ofmaximum intensity of each
observed unphosphorylated and phosphorylated site-discriminating (b and y) ion are reported in parentheses; the minus symbol indicates that the charge state could not
be determined.
Phosphorylation and inactivation of cardiac NaV1.5 channels
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positions 1938 and 1989, show increased phosphorylation in
the CaMKIIc-Tg compared with the WT ventricles.
Phosphorylation at serines 1933 and 1984 impairs FGF13-
dependent regulation of NaV1.5 channel inactivation
To determine the impact of phosphorylation at these two
C-terminal (mouse) serines 1938 and 1989 on the gating prop-
erties of NaV1.5 channels, the orthologous human serine to
glutamate (NaV1.5-S1933E/S1984E, NaV1.5-EE) or serine to
alanine (NaV1.5-S1933A/S1984A, NaV1.5-AA) double NaV1.5
phosphomutants were generated and analyzed by whole-cell
voltage-clamp analyses in transiently transfectedHEK293 cells.
Because pSer-1938 and pSer-1989 are located in close proxim-
ity to the binding site for the iFGFs (14–16, 20–22), we tested
the hypothesis that phosphorylation at these two sites disrupts
the interaction of the iFGFs with NaV1.5 and the associated
iFGFs-dependent regulation of NaV1.5 channel function. To
this purpose, initial experiments were aimed at exploring the
effects of FGF13 on the current density and biophysical prop-
erties of heterologously expressed NaV1.5 channels. The iso-
form 2 of FGF13 (FGF13–2) was chosen as the iFGF in these
experiments as it is the isoform detected in the mNaVPAN-
IPs. As illustrated in Fig. 5, thesewhole-cell voltage-clamp anal-
yses demonstrated that FGF13 significantly decreases the peak
Na current (INa) density (p 0.05, Fig. 5, A and B) and shifts
the voltage dependence of steady-state current inactivation
toward depolarized potentials (p  0.01, Fig. 5D, see detailed
densities, properties, and statistics in Table 2). In contrast, no
significant differences in the voltage dependence of activation
(Fig. 5C) or the kinetics of activation, inactivation, and recovery
from inactivation were observed upon FGF13 co-expression
(Table 2). To determine the effect of NaV1.5 phosphorylation at
Figure 4.Quantification analysis ofNaV1.5phosphorylation sites in theCaMKIIc-Tg versus theWTmNaVPAN-IPs.A, relative abundances of 32NaV1.5
phosphopeptides allowingassignments of the listedphosphorylation sites, in theCaMKIIc-Tg (n4) versus theWT (n4) IPs,were calculatedusing label-free
quantification of the (Orbitrap XL) MS1 data. The mean S.E. relative abundance of unphosphorylated NaV1.5 peptides in the CaMKIIc-Tg versus the WT IPs
was calculated from 86 unphosphorylated NaV1.5 peptides (minimumScaffold peptide probability scores of 95%). Consistent with the biochemistry data (Fig.
1) and the DAnTE protein statistical analysis (Fig. 2C), the unphosphorylated NaV1.5 peptides are 3.6-fold more represented in the CaMKIIc-Tg IPs than in the
WT IPs (red dashed line). The relative abundances of individual NaV1.5 phosphopeptides are significantly (*, p  0.05, Mann-Whitney test) different in the
CaMKIIc-Tg compared with the WT IPs. B, Tukey whisker analysis of NaV1.5 peptide relative abundance in CaMKIIc-Tg versusWT IPs. Of the 118 (86 unphos-
phorylated and 32 phosphorylated) NaV1.5 peptides, only the phosphopeptides AT(pS)DNLPVR, RL(pS)(pS)GTEDGGDDR, and AL(pS)AVSVLTSALEELEESHRK
(markedwith † inA), exhibitingphosphorylation(s) on serines 1989 (pSer-1989), 483 and484 (pSer-483 andpSer-484), and664 (pSer-664), respectively, present
fold change ratios (8.96-, 7.13-, and 0.58-fold) significantly different from the median ratio. C, mean  S.E. intensities of phosphopeptides
Q(17.03)QAGSSGLSDEDAPER, assigning pSer-1937 and/or pSer-1938 (absence in WT IPs and presence in CaMKIIc-Tg IPs), and AT(pS)DNLPVR, assigning
pSer-1989 (8.96-fold change ratio), in WT (n 4) and CaMKIIc-Tg (n 4) IPs. *, p 0.05, Mann-Whitney test. D, conservation of the two C-terminal NaV1.5
serines 1938 and 1989 across orthologs.
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serines 1933 and 1984 on these FGF13-dependent regulations,
these analyses were repeated from cells co-expressing NaV1.5-EE
or NaV1.5-AA and FGF13. These recordings revealed that the
voltage dependence of steady-state inactivation in cells co-ex-
pressing NaV1.5-EE and FGF13 is significantly (p  0.01)
shifted toward hyperpolarized potentials compared with cells
co-expressing NaV1.5-WT and FGF13 and similar to cells
expressingNaV1.5-WT alone (Fig. 5D andTable 2). In contrast,
the NaV1.5-AA phosphomutant co-expressed with FGF13
showed voltage dependence of inactivation properties similar
to those recorded from cells co-expressing NaV1.5-WT and
FGF13. No changes in peak INa density, voltage dependence of
activation, or kinetics of activation, inactivation, and recovery
from inactivation were observed with either the NaV1.5-EE or
Figure 5. Phosphorylation at serines 1933 and 1984 disrupts the FGF13-dependent increase in steady-state NaV1.5 channel availability. A, represen-
tative whole-cell voltage-gated Na currents recorded from transiently transfected HEK293 cells. Currents were obtained 48 h following transfection of
HEK293 cells with NaV1.5-WT (black), NaV1.5-WT FGF13 (green), NaV1.5-S1933E/S1984E FGF13 (NaV1.5-EE FGF13, red), NaV1.5-S1933A/S1984A FGF13
(NaV1.5-AA  FGF13, blue), NaV1.5-S1933E/S1984E (NaV1.5-EE, purple), and NaV1.5-S1933A/S1984A (NaV1.5-AA, pink) using the protocols illustrated in each
panel. B, mean  S.E. peak Na current (INa) densities are plotted as a function of test potential. C, voltage dependence of current activation. Mean  S.E.
normalized conductances (GNa) areplottedas a functionof test potential and fittedusingaBoltzmannequation.D, voltagedependenceof steady-state current
inactivation. Mean  S.E. normalized current amplitudes are plotted as a function of prepulse potential and fitted using a Boltzmann equation. FGF13
significantly (p 0.01 versus NaV1.5-WT, one-way ANOVA followed by the Dunnett’s post hoc test) shifts the voltage dependence of NaV1.5 channel inactiva-
tion toward depolarized potentials, an effect reversed with the NaV1.5-EE phosphomutant (p 0.01 versusNaV1.5-WT FGF13, one-way ANOVA followed by
the Dunnett’s post hoc test). E, no significant changes in voltage dependence of steady-state current inactivation were observed between NaV1.5-WT,
NaV1.5-EE, and NaV1.5-AA in the absence of FGF13. Detailed densities, properties, and statistics are provided in Table 2.
Phosphorylation and inactivation of cardiac NaV1.5 channels
J. Biol. Chem. (2017) 292(42) 17431–17448 17437
 at W
ashington U
niversity on January 17, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
NaV1.5-AA phosphomutants compared with the NaV1.5-WT
co-expressed with FGF13 (Fig. 5, A–C, and Table 2). In addi-
tion, no changes in the voltage dependences of inactivation
were observed between NaV1.5-WT (V1⁄2  84.5  0.6 mV,
n  24), NaV1.5-EE (V1⁄2  83.9  0.5 mV, n  18), and
NaV1.5-AA (V1⁄2  84.1  0.7 mV, n  13) in the absence of
FGF13 (Fig. 5E), suggesting that FGF13 plays a pivotal role
in mediating this phosphorylation-dependent effect. Finally,
mimicking or abolishing phosphorylation at only one of the two
phosphorylation sites (in cells co-expressing NaV1.5-S1933E,
NaV1.5-S1933A, NaV1.5-S1984E, or NaV1.5-S1984A with
FGF13) did not show any significant changes on peak INa den-
sity or channel biophysical properties compared with cells co-
expressing NaV1.5-WT and FGF13 (Table 2).
Additional voltage-clamp experiments were designed to
examine the effects of FGF13 and of NaV1.5 phosphomutants
on the late Na current. These analyses showed that the TTX-
sensitive late Na current (INaL) density is significantly (p 
0.001) smaller in cells co-expressing NaV1.5 and FGF13 than in
cells expressing NaV1.5 alone (Fig. 6, A and B, and Table 3).
Interestingly, this effect was significantly (p  0.05) abrogated
in cells co-expressing NaV1.5-EE and FGF13 (Fig. 6, A and B,
and Table 3). However, no such abrogation of the FGF13 effect
was observed with the NaV1.5-AA phosphomutant (Fig. 6, C
and D, and Table 3). In addition, similar to the biophysical
properties, no significant effects on INaL could be detected in
the absence of FGF13 (INaL0.32 0.04 pA/pF, n 27 for
NaV1.5-WT; INaL0.46 0.07 pA/pF,n 28 forNaV1.5-EE;
and INaL0.25 0.05 pA/pF, n 15 for NaV1.5-AA, see Fig.
6E) or with the simple phosphomutants (Table 3). Taken
together, these results suggest that simultaneous phosphoryla-
tion at serines 1933 and 1984 on NaV1.5 impairs the effects of
FGF13 on channel inactivation properties, which results in
decreased channel availability and increased INaL.
Phosphorylation at serines 1933 and 1984 decreases the
interaction of FGF13 and CaMwith NaV1.5
To explore the hypothesis that phosphorylation at serines
1933 and 1984 in NaV1.5 impairs the regulation of channel
inactivation mediated by FGF13 by altering the binding of
FGF13 and/or CaM to the channel, co-immunoprecipitation
experiments were completed using the same experimental par-
adigm as above. As illustrated in Fig. 7A, FGF13 and (endoge-
nous) CaM co-immunoprecipitate with NaV1.5, whether in the
WT, NaV1.5-AA, or NaV1.5-EE forms, in HEK293 cells. Inter-
estingly, however, the relative abundances of FGF13 (Fig. 7B)
and CaM (Fig. 7C) are significantly (p  0.01 and p  0.001,
respectively) lower in the NaV1.5 immunoprecipitates from
cells expressing theNaV1.5-EE phosphomutant compared with
cells expressing the WT channels. No changes were observed
with theNaV1.5-AAphosphomutant. Parallel negative controls
of co-immunoprecipitations obtained from cells transiently
transfected with FGF13 or NaV1.5-WT alone confirmed the
specificity of detected signals.Todeterminewhetherphosphor-
ylation at only one sitewas sufficient to decrease the interaction
of FGF13 or CaM with the channel, co-immunoprecipitations
were performedwith the single alanine or glutamate phosphomu-
tant channels. Consistent with the electrophysiological findings,
no significant changes in binding affinity were observed with any
of the single phosphomutant channels (Fig. 7, B andC).
Additional co-immunoprecipitation experiments were then
designed to determinewhether FGF13 andCaM influence each
other for the binding to the channel. Interestingly, these exper-
iments revealed that co-expression of FGF13 significantly (p
Table 2
Voltage-gated Na current densities and properties in transiently transfected HEK293 cells
The peak Na current density (INa), time to peak, and time course of inactivation properties presented were determined from analyses of records obtained on depolariza-
tions to 20 mV (HP  120 mV). All values are means  S.E. The number of cells analyzed is provided in parentheses. *, p  0.05; **, p  0.01; ***, p  0.001 versus
NaV1.5-WT; ##, p 0.01 versus NaV1.5-WT FGF13; one-way ANOVA followed by the Dunnett’s post-hoc test.
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0.01) increases the binding of CaM to NaV1.5 (Fig. 7, D and E).
Conversely, overexpression of CaM did not influence the bind-
ing of FGF13 to the channel (Fig. 7, D and E). Additionally, no
changes in the binding of CaM to NaV1.5-EE or NaV1.5-AA,
compared with NaV1.5-WT, were observed in the absence of
FGF13 (Fig. 7F). Together, these biochemical analyses suggest
that FGF13 potentiates the binding of CaM to NaV1.5 and that
phosphorylation at both serines 1933 and 1984 decreases
the interaction of FGF13 and, consequently, of CaM with the
channel.
Figure6. Phosphorylationat serines1933and1984disrupts theFGF13-dependentdecrease in INaL.TTX-sensitive lateNa
 current (INaL) recordingswere
obtained 48 h after transfection of HEK293 cells in three different data sets. The first data set (A and B) was obtained from cells expressing NaV1.5-WT (black),
NaV1.5-WT  FGF13 (green), and NaV1.5-S1933E/1984E  FGF13 (NaV1.5-EE  FGF13, red); the second data set (C and D) from cells expressing NaV1.5-WT
(black), NaV1.5-WT FGF13 (green), andNaV1.5-S1933A/S1984A FGF13 (NaV1.5-AA FGF13,blue); and the third data set (E) fromcells expressingNaV1.5-WT
(black), NaV1.5-S1933E/S1984E (NaV1.5-EE, purple), and NaV1.5-S1933A/S1984A (NaV1.5-AA, pink). A and C, representative TTX-sensitive INaL recordings evoked
by prolonged depolarizations (350 ms at 20 mV) from a holding potential of 120 mV. The scale bars indicate a current amplitude of 10 pA, which
corresponds to a current density of 0.8 pA/pF and time (50ms). B, D, and E, distributions andmean S.E. TTX-sensitive late Na current (INaL) densities. *, p
0.05; ***, p 0.001 versus NaV1.5-WT; #, p 0.05 versus NaV1.5-WT FGF13; ns, non-significant; Kruskal-Wallis one-way ANOVA followed by the Dunn’s post
hoc test. Detailed densities and statistics are provided in Table 3.
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Discussion
The results presented here provide two novel phosphoryla-
tion maps of native mouse NaV1.5 channel subunits purified
from control WT and failing CaMKIIc-overexpressing ventri-
cles, and they delineate two novel C-terminal phosphoserines,
at positions 1938 and 1989, that are up-regulated in the failing
CaMKIIc-overexpressing ventricles. Mechanistic analyses in
HEK293 cells revealed that mimicking phosphorylation at both
sites (in the human sequence) impairs the regulation of NaV1.5
channels by FGF13, resulting in decreased channel availability
and increased late Na current. Co-immunoprecipitation
experiments demonstrated that FGF13 potentiates the binding
of CaM to NaV1.5 and that FGF13 and, consequently, CaM
bindings are decreased when phosphorylation at both sites is
mimicked. Overall, these results provide evidence for a novel
phosphorylation-dependentmechanism that acts at the level of
the NaV1.5 channel macromolecular complex through regula-
tion of specific protein/protein interactions.
CaMKIIc-dependent phosphorylationmap of nativemouse
NaV1.5 channels
The present phosphoproteomic analysis confidently identi-
fied a total of 19 native phosphorylation sites in the NaV1.5
channel proteins purified frommouse ventricles, of which nine
are novel. Consistent with our previous MS analysis (31), and
with another phosphoproteomic analysis of human NaV1.5
channels purified fromHEK293 cells (9), the great majority (13
of 19) of identified phosphorylation sites are located in the first
intracellular linker loop of the channel, suggesting critical roles
for this region in mediating phosphorylation-dependent regu-
lation of cardiac NaV1.5 channels. However, none of these 13
phosphorylation sites identified in the first linker loop, includ-
ing phosphoserine 571whichwas reported to be CaMKIIc-de-
pendent (11, 12), appeared to be regulated in the CaMKIIc-Tg
ventricles compared with the WT ventricles. Note that no rel-
ative quantification could be obtained for the low abundance
phosphopeptides assigning phosphoserines 516 and 1888, and
that the region surrounding threonine 594 was not covered
(Fig. 2B), precluding possible detection and quantification of
phosphothreonine 594. The only two/three phosphorylation
sites showing significant and consistent abundance changes in
theCaMKIIc-Tg comparedwith theWTventricles are located
in the CTD of NaV1.5, at position(s) 1937 and/or 1938 and at
position 1989. Although localization(s) of phosphorylation
could not be discriminated between serines 1937 and 1938
in the singly phosphorylated peptide allowing quantification
(presence in the CaMKIIc-Tg IPs, and absence in theWT IPs),
we focused our attention on serine 1938 (human serine 1933)
because serine 1937 is not well-conserved across species and is
notably absent in human. In addition, the humanNaV1.5 phos-
phoserine 1933 has previously been shown to be CaMKIIc-de-
pendent in in vitro phosphoproteomic analyses (9), underscor-
ing the potential involvement of CaMKIIc in phosphorylating
this site. Finally, it is also important to note here that the relative
quantification of the doubly phosphorylated peptide support-
ing phosphorylation at both serines 1937 and 1938 (Table 1)
could not be obtained because of low abundance, yet this pep-
tide was only detected in the CaMKIIc-Tg IPs. The number of
phosphorylation sites identified here in association with the
overexpression of CaMKIIc in mouse ventricles (two phos-
phoserines) could seem little compared with the results of the
previous phosphoproteomic study of human NaV1.5 channels
in which 23 phosphorylation sites, of the 34 identified, were
found to be phosphorylated in vitro by CaMKIIc. These seem-
ingly distinct findingsmight reflect the fact that different exper-
imental approaches were employed. Indeed, although phos-
phorylation sites were identified from native, in situ phosphor-
ylated NaV1.5 channels in this study, previous MS analysis was
performed from heterologously-expressed NaV1.5 channels
that were immunoaffinity-purified and subsequently subjected
to in vitro phosphorylation by recombinant CaMKIIc. It is also
stressed here that although the present MS analysis was per-
formed from ventricles in which CaMKIIc is overexpressed,
we cannot exclude the involvement of other kinases/phospha-
tases whose activity may also be changed. Consistent with the
direct implication of CaMKIIc, however, the in vitro phospho-
proteomic analyses of human NaV1.5 demonstrated that
human phosphoserine 1933 is CaMKIIc-dependent (9). Like-
wise, it is interesting to note that mouse phosphoserine 1989
(and human phosphoserine 1984) is located in awell-conserved
consensus CaMKII phosphorylation site (37). Together, these
MS analyses from mouse ventricles therefore suggest that the
two NaV1.5 phosphoserines at positions 1938 and 1989 are
associated with the overexpression of CaMKIIc.
Table 3
Late Na current densities in transiently transfected HEK293 cells
The TTX-sensitive late Na current (INaL) densities were measured at20 mV (HP120 mV). All values are means S.E. The number of cells analyzed is provided in
parentheses. *, p 0.05; ***, p 0.001 versusNaV1.5-WT; #, p 0.05 versusNaV1.5-WT FGF13; Kruskal-Wallis one-way ANOVA followed by the Dunn’s post-hoc test.
Phosphorylation and inactivation of cardiac NaV1.5 channels
17440 J. Biol. Chem. (2017) 292(42) 17431–17448
 at W
ashington U
niversity on January 17, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FGF13-dependent regulation of NaV1.5 channel inactivation
Because our MS findings converged on the possible involve-
ment of NaV1.5 C-terminal phosphorylation sites in mediating
CaMKIIc-dependent channel regulation and that the CTD of
NaV channels is well-recognized for its role in regulating chan-
nel inactivation through the binding of iFGFs (15, 20–26) and
CaM (13–19), we first characterized the roles of FGF13 in reg-
ulating NaV1.5 channels in HEK293 cells. Our findings are in
accordance with previous data demonstrating a key role for
FGF13 in increasing steady-state NaV1.5 channel availability,
although the amplitude of the presently observed effect (2
mV) is smaller than previously reported effects of FGF13 or
Figure 7. Phosphorylation at serines 1933 and 1984 decreases the interaction of FGF13 and consequently of CaM with NaV1.5. Forty eight hours
following transfection of HEK293 cells with NaV1.5-WT, NaV1.5-S1933A/S1984A (NaV1.5-AA), NaV1.5-S1933E/S1984E (NaV1.5-EE), NaV1.5-S1933A (1933A),
NaV1.5-S1933E (1933E), NaV1.5-S1984A (1984A), NaV1.5-S1984E (1984E), FGF13, and/or CaM, cell lysates were prepared and used for IPs with the mNaVPAN
antibody. A, D, and F, representative Western blots of the lysates (left panel) and the immunoprecipitates (right panel) with the monoclonal anti-NaVPAN,
anti-FGF13, and/or anti-CaM antibodies. Relative mean S.E. FGF13 (B) and CaM (C) abundances in mNaVPAN-IPs from cells expressing NaV1.5-WT (WT, n
8), NaV1.5-AA (AA, n  8), and NaV1.5-EE (EE, n  8); NaV1.5-WT (WT, n  5 and 4, respectively), 1933A (n  6 and 4, respectively), and 1933E (n  6 and 4,
respectively); and NaV1.5-WT (WT, n 6), 1984A (n 6), and 1984E (n 6). E, relative mean S.E. CaM abundances in mNaVPAN-IPs from cells expressing
NaV1.5-WT (n  8) and NaV1.5-WT  FGF13 (n  12), and FGF13 abundances in mNaVPAN-IPs from cells expressing NaV1.5-WT  FGF13 (n  4) and NaV
1.5-WT FGF13 CaM (n 4). **, p 0.01; ***, p 0.001 versusNaV1.5-WT, Kruskal-Wallis one-way ANOVA followed by the Dunn’s post hoc test (B and C), or
Mann-Whitney test (E). FGF13 and CaM abundances in each IP were first normalized to immunoprecipitated NaV1.5 and then expressed relative to FGF13 or
CaM abundances in IPs from control conditions.
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other iFGFs (5–10 mV) (15, 20–26). Interestingly, our data
also provide a novel role for FGF13 in decreasing the late Na
current inHEK293 cells. The role of FGF13, and in particular of
FGF13-2, in regulating the late Na current had only been
investigated once in tsA201 cells, and it was shown to have no
effect (26). These different findings perhaps are due to differ-
ences in the heterologous expression systems used or are due to
the fact that no NaV subunits were included in the previous
study compared with this study in which NaV1.5 channels were
co-expressed with FGF13–2 and NaV1. Consistent with this
negative effect of FGF13 on the late Na current, the condi-
tional knock-out of FGF13 in murine hearts revealed longer
action potential durations (25), which could well be caused by
an increased late Na current. The answer to this question
must await further analysis of the late Na current from this or
other FGF13 animal models. The observed decrease in peak
Na current density upon FGF13 co-expression was somewhat
surprising in light of previous findings in native cardiomyocytes
demonstrating a decreasedNaV1.5 channel cell-surface expres-
sion upon FGF13 knockdown (21) or a reduced peak Na cur-
rent density in ventricular myocytes isolated from FGF13
conditional knock-out mice (25). This lack of consistency is
nonetheless reminiscent of previous investigations of iFGF-de-
pendent regulation of NaV channels from Pitt and co-workers,
who reported the same disparate effects on peak Na current
density in native (increase) (21, 25) and heterologous (decrease)
(26) cells, and it may reflect differences in channel cellular and
molecular environment. In addition, note that no differences in
peak Na current densities were observed in ventricular
myocytes isolated from FGF13 knock-out andWTmice (24).
In summary, these results suggest that FGF13 primarily reg-
ulates the inactivation properties of NaV1.5 channels from
both the closed state (increased availability) and the open
state (decreased late Na current).
Impairment of FGF13-dependent NaV1.5 channel inactivation
by phosphorylation
Determination of the impact of phosphorylation at serines
1933 and 1984 in the regulation of NaV1.5 channels first
revealed that the binding of FGF13 and CaM to NaV1.5 is
reduced with the double-glutamate phosphomutant compared
with the WT channels, suggesting that phosphorylation at
these serines disables the interaction of FGF13 and CaM with
the channel. Most importantly, this reduced interaction, as
assessed by co-immunoprecipitation, correlates with an im-
pairment of functional modulation. Indeed, all the effects of
FGF13 on NaV1.5-generated currents, but those on the peak
density were nearly completely abolished with the double-glu-
tamate phosphomutant, therefore resulting in decreased chan-
nel availability and increased late Na current. Together, these
analyses show that mimicking phosphorylation at serines 1933
and 1984, which according to these and previous findings (9)
are not phosphorylated at baseline in HEK293 cells, impairs
FGF13-dependent regulation of NaV1.5 channel inactivation.
Of note, these functional effects associated with the decreased
FGF13 and CaM bindings are similar to those previously
observed with several NaV1.5 mutants in which the binding of
CaM to the NaV1.5 CTD is disrupted (17, 19, 29). Mimicking
phosphorylation at only one site, however, did not lead to any
consistent alterations in the interaction of FGF13 or CaM with
the channel nor in the functional regulation by FGF13, suggest-
ing that phosphorylation at both sites is necessary to disable
FGF13/CaM bindings and associated dysregulation of channel
inactivation. Consistent with these findings in HEK293 cells,
ourMS analyses also revealed different relative compositions of
associated/regulatory proteins in NaV1.5 channel complexes in
the CaMKIIc-Tg ventricles compared with theWT ventricles.
Of particular interest, indeed, the FGF13 and CaM relative
abundances in theCaMKIIc-Tg IPs comparedwith theWT IP,
are lower (2-fold abundance ratios) than the 3-fold abundance
ratios obtained for NaV1.5 or ankyrin-G. Together, therefore,
these analyses suggest that phosphorylation at serines 1933 and
1984 impairs the binding of FGF13 and CaM toNaV1.5 and abro-
gates FGF13-dependent regulation of channel inactivation.
FGF13 potentiates the binding of CaM to NaV1.5, and
phosphorylation-dependent disruption of FGF13 binding
to NaV1.5 results in reduced CaMbinding
To further delineate the relationship between FGF13 and
CaM for the binding to NaV1.5 and subsequent phosphoryla-
tion-dependent regulation, the same electrophysiological and
biochemical analyses were performed in the absence of FGF13.
Interestingly, neither the channel availability nor the late Na
current or the CaM/NaV1.5 interaction were altered in the
absence of FGF13, highlighting the primary role of FGF13
in this phosphorylation-dependent regulation. These findings
also suggest that the decreased CaM binding to the double-
glutamate phosphomutant channel is subsequent to the de-
creased FGF13 binding. In this respect, further co-immunopre-
cipitation experiments were performed to examine the
relationship between FGF13 and CaM for the binding to
NaV1.5. Remarkably, these analyses revealed that FGF13 sub-
stantially increases the binding of CaM to the channel, demon-
strating for the first time that the binding of CaM to NaV1.5 is
potentiated by the binding of FGF13. Inversely, no changes in
FGF13 binding were observed upon CaM overexpression, sug-
gesting that CaM does not influence the binding of FGF13.
Whether phosphorylation or FGF13 influence directly the
Ca2/CaM dependence of NaV1.5 channel inactivation
remains to be investigated. Interestingly, these novel findings
are evocative of recent observations from the Pitt group (29)
demonstrating that the increased late Na current associated
with several LQT3 syndrome mutations within the NaV1.5
CTD correlates with a decreased binding of apoCaM to the
NaV1.5 CTD. In line with these findings, the recently reported
LQT3-causingmutation at p.H1849R in theNaV1.5CTD is also
associated with an impairment of iFGF binding and iFGF-me-
diated regulation of NaV1.5 channels (28). Together with these
two previous studies, our results herein support the overall
hypothesis that the binding of FGF13 and/or CaM to the
NaV1.5 CTD is pivotal in the regulation of channel inactivation,
as unveiled by C-terminal phosphorylation and disease muta-
tions within the NaV1.5 CTD, and that impairment of iFGF
and/orCaMmodulationmay constitute a commonmechanism
to inherited (CTD-mutated LQT3 patients) and acquired
(CaMKIIc-associated) arrhythmias.
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Potential broader implication of phosphorylation-dependent
regulation of NaV1.5 channels in heart failure
Evidence suggests that some of the arrhythmogenic abnor-
malities associated with heart failure are triggered by the acti-
vation of CaMKII (2, 30) and a subsequent CaMKII-dependent
increase in INaL (4–7). By identifying two novel NaV1.5 phos-
phorylation sites up-regulated in CaMKIIc-Tg ventricles,
which are failing (30), and by demonstrating roles for these sites
in altering NaV1.5 channel inactivation, our results provide evi-
dence for a model in which increased CaMKIIc-dependent
NaV1.5 phosphorylation at serines 1933 and 1984 may provide
an arrhythmic substrate in heart failure. Nonetheless, it is
unclear whether the functional consequences of impaired
FGF13 and CaM binding to NaV1.5 by phosphorylation, as
observed here in HEK293 cells, fully match up with the NaV
channel defects associated with heart failure. Indeed, although
the increased late Na current is a consistent finding in failing
cardiomyocytes from both human and animal models (2, 4–7,
38), evidence for a decreased NaV channel availability has only
been observed, to our knowledge, in the CaMKIIc-Tgmice (7)
and in a failing dog model induced by left-bundle branch abla-
tion and right atrial pacing (2). Besides, the activation of CaM-
KII has consistently been associated with an increased INaL and
a decreased NaV1.5 channel availability (3, 7, 8, 11, 12). Overall,
the molecular mechanisms elucidated here may be relevant in
conditions of increased CaMKIIc expression and/or activity
and may partly contribute to the arrhythmias associated with
heart failure.
Experimental procedures
Animals were handled in accordance with the guidelines
from Directive 2010/63/EU of the European Parliament on the
protection of animals used for scientific purposes. Experimen-
tal protocols were approved by the local animal care and use
committee (Comite´ d’Ethique pour l’Expe´rimentation Animale
des Pays de la Loire, authorization CEAA.2010.9). Generation
and characterization of the CaMKIIc-Tgmouse line have been
described previously (30). Cardiac tissues for in vitro experi-
ments were harvested after euthanasia of the mice by cervical
dislocation.
Immunoprecipitations of NaV channel complexes
Flash-frozen ventricles from four 13-month-old CaMKIIc-
Tg and four age- and sex-matchedWTmicewere homogenized
as described previously (31) in ice-cold lysis buffer containing
20 mMHEPES (pH 7.4), 150 mMNaCl, 0.5% amidosulfobetaine
(Sigma), 1 complete protease inhibitor mixture tablet (Roche
Applied Science), 1 mM phenylmethylsulfonyl fluoride (PMSF,
Interchim), 0.7 g/ml pepstatin A (Thermo Fisher Scientific),
and 1 Halt phosphatase inhibitor mixture (Thermo Fisher
Scientific). After a 15-min rotation at 4 °C, 8 mg of the pooled
WTorCaMKIIc-Tg ventricular soluble protein fractions were
pre-cleared with 200 l of protein G-magnetic beads (Pierce)
for 1 h and subsequently used for IPs with 48 g of an anti-
NaVPAN mouse monoclonal antibody (mNaVPAN, Sigma,
S8809), raised against the SP19 epitope (39) located in the third
intracellular linker loop and common to all NaV  subunits.
Prior to the IP, antibodies were cross-linked to 200 l of pro-
tein G-magnetic beads using 20 mM dimethyl pimelimidate
(Thermo Fisher Scientific) (40). Protein samples and antibody-
coupled beads were mixed for 2 h at 4 °C. Magnetic beads were
then collected and washed rapidly four times with ice-cold lysis
buffer, and isolated protein complexes were eluted from the
beads in 2% Rapigest (41) (Waters), 8 M urea (Sigma), 100 mM
Tris (pH 8.5) at 37 °C for 30 min.
For co-immunoprecipitations of heterologously expressed
proteins, HEK293 cells were washed twice with PBS and lysed
in lysis buffer (as above) 48 h after transfection. Soluble pro-
tein fractions were collected and incubated with 12.5 l of
mNaVPAN-coupled magnetic beads (as above). After a 2-h
incubation at 4 °C, beads were washed four times in lysis buffer,
and protein complexes were eluted with 1 SDS sample buffer
at 60 °C for 5 min.
Gel electrophoreses andWestern blot analyses
Ten percent of the immunoprecipitated mouse ventricular
NaV channel protein complexes were fractionated on one-
dimensional polyacrylamide gels and analyzed using either
SYPRO Ruby (Life Technologies, Inc.) staining or Western
blotting using themNaVPANantibody (1:2000, Sigma, S8809)
as described previously (31). The total ventricular lysates were
blotted with a rabbit polyclonal anti-NaV1.5 antibody (1:2000,
RbNaV1.5, Alomone, ASC-005).Western blot analyses of pro-
tein eluates from co-immunoprecipitations of heterologously
expressed proteins were performed using the following pri-
mary antibodies: mouse monoclonal anti-NaVPAN (1:2000,
mNaVPAN, Sigma, S8809); mouse monoclonal anti-FGF13
(1:300, cloneN91/27, NeuroMab Facility, University of Califor-
nia Davis, NINDS/NIMH, National Institutes of Health); and
rabbit monoclonal anti-CaM (1:300, Abcam, EP799Y). Bound
antibodies were detected using horseradish peroxidase-conju-
gated goat anti-rabbit or anti-mouse secondary antibodies
(SantaCruzBiotechnology), and protein signalswere visualized
using the SuperSignalWest Dura Extended Duration Substrate
(Pierce). The intensities of co-immunoprecipitated FGF13 or
CaM bands were normalized to the intensities of immunopre-
cipitated NaV1.5 bands from the same IP sample, and FGF13 or
CaM abundances in immunoprecipitations from experimental
conditions are expressed relative to abundances in immuno-
precipitations from control conditions.
In-solution endoprotease digestions
Samples for mass spectrometry were prepared as described
previously (31). Briefly, eluted proteins were precipitated using
the 2D protein clean-up kit (GEHealthcare). The resulting pel-
lets were dissolved in 8 M urea, 100 mM Tris (pH 8.5), reduced
with 5mM tris(2-carboxyethyl)phosphine (pH 8.0) for 30min at
room temperature, and alkylated with 10 mM iodoacetamide
(Bio-Rad) for 30 min at room temperature. Samples were then
digested with 1 g of endoproteinase Lys-C (Roche Applied
Science) overnight at 37 °C and subsequently with 4g of tryp-
sin (Sigma) overnight at 37 °C. Peptides were acidified with for-
mic acid to a final concentration of 1%, extracted with NuTip
porous graphite carbon wedge tips (Glygen), and eluted with
aqueous acetonitrile (ACN, 60%) containing formic acid (FA,
0.1%). The extracted peptides were dried, dissolved in aqueous
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ACN/FA (1%/1%), stored at80 °C, and subsequently analyzed
using one-dimensional liquid chromatography-tandem mass
spectrometric experiments (LC-MS/MS).
Mass spectrometric analyses
Peptide mixtures were analyzed using nano-LC-MS on three
high-resolution hybrid mass spectrometers, a linear quadru-
pole ion trap Orbitrap XL (LTQ-Orbitrap XL) (31), an LTQ-
Orbitrap Elite (42) (both from Thermo Fisher Scientific), and a
TripleTOF 5600 Plus (SCIEX) (43). The chromatograph was a
2D Plus (Eksigent) LC with a Nanoflex module and AS2
autosampler in dual cHiPLC columns (ChromXP C18 200
m  15 cm; particle size 3 m, 120 Å) configuration. The
mobile phases were 1% FA in water (A) and 1% FA in ACN (B).
The liquid chromatographs were interfaced to the mass spec-
trometers through a nanospray source (PicoView PV550, New
Objective). The samples were loaded in a volume of 5–10 l at
a flow rate of 1.5l/min followed by organic gradient elution of
peptides (800 nl/min). The LC conditions for analyses on the
LTQ-Orbitrap XL and LTQ-Orbitrap Elite were performed
after equilibrating the columns in 98% solvent A and 2% solvent
B followed by 2% B, 0–5 min; 2- 25% B, 5–110 min; 25–80% B,
110–170 min; 80–2% B, 170–175 min; and isocratic elution at
2% B, 175–190 min. The survey scans (m/z 350–2000) (MS1)
were acquired at high resolution (60,000 at m/z 400) in the
Orbitrap XL, and the MS2 spectra were acquired in the linear
ion trap at low resolution, both in profile mode. The maximum
injection times for the MS1 scans in the Orbitrap and the LTQ
were 500 and 200 ms, respectively. The automatic gain control
targets for the Orbitrap and the LTQwere 5 105 and 3 104,
respectively, with maximum injection times of 100 ms for the
MS2 scans. The MS1 scans were followed by three MS2 events
in the linear ion trap with collision activation in the ion trap
(parent threshold 1000, isolation width 2.0 Da, normalized col-
lision energy 30%, activation Q 0.250, and activation time 30
ms). Dynamic exclusion was enabled (0.20/1.0 Da) for 90 s
afterMS2 acquisitions. A repeat count of 1, a repeat duration of
45 s, and a maximal exclusion list size of 500 were used. The
following ion source parameters were used: capillary tempera-
ture 200 °C, source voltage 3.0 kV, source current 100 A, cap-
illary voltage 33 V, and tube lens 120 V. Data were acquired
using XCalibur, version 2.2 SP1 (Thermo Fisher Scientific). For
data acquisition on the LTQ-Orbitrap Elite, the followingmod-
ifications were employed. The survey scans (m/z 300–1650)
were acquired at a resolution of 120,000 with a target value of
1e6 ions. The HCD MS2 acquisitions were performed for the
top 15most intense ions at a resolution of 15,000, a target value
of 40,000 and a low mass setting of 120 m/z. For collision-in-
duced dissociation, a collision energy of 40% was used with an
activation time of 100 ms. Dynamic exclusion was enabled (30
s) withoutMS2 acquisition of1 charged parent ions. The data
were acquired using Xcalibur, version 2.0.7 (Thermo Fisher
Scientific).
The LC-MS analysis on the TripleTOF 5600 Plus mass
spectrometer was obtained using the following gradient elution
program: 0 time, 98%A, 2%B; 5min, 2%A, 98%B; 415min, 65%
A, 35% B; and 440 min, 20% A, 80% B. Initial chromatographic
conditions were restored in 5 min and maintained for 20 min.
The ion spray voltage was set at 2.9 kV, the curtain gas at
10 p.s.i., the nebulizer gas at 14 p.s.i., and the interface heater
temperature set at 175 °C. The MS1 data were acquired at a
resolution of 25,000 with a scan range of 400–1200m/z in 250
ms. The top 50 product ions were selected for MS2 acquisition
with a dwell time of 100 ms. Four time bins were summed for
each scan at a frequency of 15.4 kHz (throughmonitoring of the
40 GHz multichannel TDC detector with four-anode/channel
detection). A rolling collision energy (CE) was applied to all
precursor ions for collision-induced dissociation using the fol-
lowing equation: CE slopem/z intercept, where the slope
for all charge states above2 is 0.0625 and the intercept is3,
5, and6 for2,3, and4, respectively.
MS data processing and analyses
The LC-MS raw files from the LTQ-Orbitrap XL and Elite
were processed using MASCOT Distiller (version 2.3.02,
Matrix Science) with settings previously described (31). The
TripleTOFdatawere processed using the SCIEXMSDataCon-
verter (version 1.3, SCIEX), converting the raw data files (*.wiff)
to mgf files. The resulting MS2 centroid files were used for
database searching with MASCOT (version 2.3.02) against the
UNIPROT mouse protein database (downloaded on May 2,
2011, with 72,510 entries for the XL data, and on December 20,
2011, with 77,200 entries for the Elite and the TripleTOF data)
using the following parameters: trypsin as the enzyme, MS tol-
erances of 50 (XL), 10 (Elite), and 25 (TripleTOF) ppm;MS/MS
tolerances of 0.8 (XL), 0.05 (Elite), and 0.1 (TripleTOF)Da, with
a fixed carbamidomethylation of Cys residues and variable
modifications being oxidation (Met), pyro-glutamination
(Gln), and phosphorylation (Ser, Thr, and/or Tyr), a maximal
number of missed cleavages of 4, and 1, 2, 3, and 4
charge states. Scaffold (versions 3.1.4.1 (XL), 4.4.3 (Elite) and
3.6.4 (TripleTOF), Proteome software) was used to validate
MS2-based peptide and protein identificationswith the Peptide
(44) and Protein (45) Prophet algorithms using thresholds of 50
and 95%, respectively. The supplemental Tables 1–3 provide
the complete lists of identified peptides and proteins using the
LTQ-Orbitrap XL, Elite, and the TripleTOF mass spectrome-
ters, respectively.
Phosphopeptide spectra were manually interpreted by com-
paring the observedmass values from the spectrum inXCalibur
(LTQ-Orbitrap XL and Elite data) or PeakView (TripleTOF
data) with the theoretical parent and fragmentNaV1.5 ionmass
values from MS-Product. Annotations of MS2 spectra were
first automated using java-based software, which matches ob-
served m/z values with theoretical fragment masses from
MS-Product, and definitive annotations were subsequently
obtained bymanual verification and interpretation.Mass accu-
racy tolerances of 20 ppm or 0.5 Da were used as guidelines for
high- and low-resolution spectral annotations, respectively,
and only those ions with mass errors within these ranges were
included to determine residue coverage and location of phos-
phorylation site(s). Additionally, for spectral annotation of
high-resolutionMS2 data, charge states of observed parent and
fragment ions were determined, and only precursor, b- and
y-ions with confirmed charge states (i.e. with at least the pres-
ence of the 13C isotope peak) were used. The phosphorylation
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site assignments were based on the presence or absence of the
unphosphorylated and phosphorylated b- and y-ions flanking
the site(s) of phosphorylation, ions that we call site-discrimi-
nating ions throughout this study. When site-discriminating
ionswere not all detected, assignments of phosphorylation sites
were narrowed down to one, two (for pSer-524 and/or pSer-
525), or four (for pSer-36, pThr-38, pSer-39, and/or pSer-42)
possibility(ies) by elimination. In addition to mass accuracy
and charge state, the relative percentage of maximum inten-
sity of site-discriminating ions or of any supporting ions in
each analyzed spectrum was also considered for spectral
annotation. Representative MS1 and MS2 spectra used for
each of the phosphorylation site assignments, mass errors of
parent ions (in ppm), and Mascot Ion scores for each phos-
phopeptide are presented in supplemental Fig. 1. The defini-
tion of all observed site-discriminating ions, as well as the
calculated mass errors and charge state confirmations for all
supporting b- and y-ions (as well as for, when detected, the
loss of phosphoric acid peaks) are summarized in Table 1
and supplemental Tables 4.
The label-free quantitativeMS analysis of protein abundance
in the IPs was performed from the entire (LTQ-Orbitrap XL)
MS1 peptide data set using the DAnTE (Data Analysis Tool
Extension) software (33–35). To perform label-free quantita-
tive analyses of mass spectra of precursor ion (MS1 peptides)
data, the LTQ-Orbitrap XL MS1 and MS2 data from
quadruplicate analyses of mNaVPAN-IPs from WT and
CaMKIIc-Tg mouse ventricles were imported into Rosetta
ElucidatorTM (version 3.3, Rosetta Biosoftware) for retention
time and m/z alignment of the peptide ion chromatograms
using previously described parameters (36). Peak intensities of
MS1 peptide features were quantified, and normalization of
intensities across samples was performed using the average sig-
nal intensities obtained in each sample. Ion chromatograms
and isotopic distributions of aligned NaV1.5 peptides were all
visually inspected.
Plasmids
The simple and double NaV1.5 phosphomutant constructs
were generated by mutating the serines 1933 and/or 1984 to
alanine(s) or glutamate(s) by site-directed mutagenesis of the
pCI-NaV1.5 plasmid containing the human NaV1.5 hH1C
cDNA (46) (NCBI Reference Sequence NM_000335) using the
QuikChange II XL site-directedmutagenesis kit (Agilent Tech-
nologies) with the following primers (with mutations under-
lined): NaV1.5-S1933A-F, 5	-cagcaggcgggcgccggcctctccga, and
NaV1.5-S1933A-R, 5	-tcggagaggccggcgcccgcctgctg; NaV1.5-
S1933E-F, 5	-cgtcagcaggcgggcgaaggcctctccgaagag, and NaV1.5-
S1933E-R 5	-ctcttcggagaggccttcgcccgcctgctgacg; NaV1.5-S1984A-F,
5	-tgtcactagagccaccgccgataacctccaggtg, and NaV1.5-S1984A-R
5	-cacctggaggttatcggcggtggctctagtgac; NaV1.5-S1984E-F 5	-
agtgtcactagagccaccgaagataacctccaggtgcgg, and NaV1.5-S1984E-R
5	-ccgcacctggaggttatcttcggtggctctagtgacact. The mutated con-
structs were then digested with restriction endonucleases to
excise the mutated fragments, which were then subcloned
into the original pCI-NaV1.5 plasmid. The human NaV1
(NM_001037, a gift from A. L. George) and rat CaM
(NM_017326, a gift from I. Deschenes) cDNAs were subcloned
into pRc/CMV and pcDNA3, respectively. The human tran-
script variant 2 of FGF13 (FGF13–2, NM_001139500), sub-
cloned intopCMV6-XL5,waspurchased fromAmsbio.All con-
structs were sequenced to ensure that no unintentional
mutations were introduced.
Culture and transient transfections
HEK293 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Life Technologies, Inc.) supple-
mented with 10% fetal bovine serum, 100 units/ml penicillin,
and 100g/ml streptomycin, in 37 °C, 5% CO2, 95% air incuba-
tor. Cells were transiently transfected at 70–80% confluence in
35-mmdisheswith 0.9g of theWTorphosphomutantNaV1.5
plasmid, 0.45g of theNaV1 plasmid, with or without 0.45g
of the FGF13 plasmid using 2 l of Lipofectamine 2000 (Life
Technologies, Inc.) following the manufacturer’s instruc-
tions. For patch-clamp recordings, transfections also con-
tained 0.2 g of the pEGFP plasmid (enhanced green fluo-
rescent protein plasmid, Clontech), so that the enhanced
GFP expression serves as amarker of transfection. The absolute
amounts of the various constructs were calculated, and the
empty pcDNA3.1 plasmid (Life Technologies, Inc.) was used as
a filler plasmid to keep the total DNA constant at 2 g in each
transfection.
Electrophysiological recordings
Whole-cell NaV currents were recorded at room tempera-
ture from transiently transfected HEK293 cells using an Axo-
patch 200A amplifier (Axon Instruments) 48 h after transfec-
tion. Voltage-clamp protocols were applied using the pClamp
10.2 software package (Axon Instruments) interfaced to the
electrophysiological equipment using a Digidata 1440A digit-
izer (Axon Instruments). Current signalswere filtered at 10 kHz
prior to digitization at 50 kHz and storage. Patch-clamp
pipettes were pulled from borosilicate glass (outer diameter is
1.5 mm and inner diameter is 0.86 mm, Sutter Instrument)
using a P-97 micropipette puller (Sutter Instrument), coated
with wax, and fire-polished to a resistance between 1.5 and 2.5
megohms when filled with internal solution. The internal solu-
tion contained (inmM): NaCl 5, CsCl 105, HEPES 10, glucose 5,
EGTA 10, CaCl2 8.7 (1 M free [Ca2], calculated with Max-
Chelator) and Mg-ATP 5 (1 mM free [Mg2], MaxChelator)
(pH 7.2 with CsOH,300mosM). The external (lowNa) solu-
tion contained (inmM):NaCl 25, CsCl 94, tetraethylammonium
chloride 25,HEPES 10, glucose 5, CaCl2 1,MgCl2 2 (pH7.4with
CsOH, 300 mosM). All the chemicals were purchased from
Sigma. After establishing the whole-cell configuration, 3 min
were allowed to ensure stabilization of the voltage dependence
of inactivation properties, at which time 25-ms voltage steps to
10mV froma holding potential (HP) of70mVwere applied
to allow measurement of whole-cell membrane capacitance,
input, and series resistances. Only cells with access resistance
7 megohms were used, and input resistances were typically

5 giga-ohms. After compensation of series resistance (80%),
the membrane was held at a HP of120 mV, and the voltage-
clamp protocols were carried out as indicated below. Leak cur-
rents were always200 pA at theHP (120mV) and corrected
Phosphorylation and inactivation of cardiac NaV1.5 channels
J. Biol. Chem. (2017) 292(42) 17431–17448 17445
 at W
ashington U
niversity on January 17, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
off line. Cells exhibiting peak current amplitudes 500 or

5000 pA were excluded from analyses.
Datawere compiled and analyzed usingClampFit 10.2 (Axon
Instruments), Microsoft Excel, and Prism (GraphPad Soft-
ware). Whole-cell membrane capacitance (Cm) was deter-
mined by analyzing the decays of capacitive transients elicited
by the 25-ms voltage steps to 10 mV from the HP (70 mV)
prior to compensation. Cmwas calculated by dividing the inte-
grated capacitive transients by the voltage. Input resistance was
calculated from the steady-state currents elicited by the same
10-mV steps (from the HP). Series resistance was calculated
by dividing the decay time constants of the capacitive transients
(fitted with a single exponential) by the Cm. To determine the
current-voltage relationships, currents were elicited by 50-ms
depolarizing pulses from80 to40 mV in 5-mV increments
from aHP of120mV (5-s inter-pulse duration). Peak current
amplitudes at each voltage step were defined as the maximal
current amplitudes. Current amplitudes were corrected by leak
currents (calculated at each voltage step from the leak current
measured at the HP) and normalized to the Cm. To analyze the
voltage dependence of activation properties, current ampli-
tudes at each voltage step were transformed to conductances
(G), and conductance-voltage relationships were fitted with the
Boltzmann equation G Gmax/(1 exp ( (Vm V1⁄2)/k)), in
whichV1⁄2 is themembrane potential for half-activation, and k is
the slope factor. The time course of inactivation ofmacroscopic
current was fitted with the double exponential function I(t) 
Aslow exp(t/slow)Afast exp(t/fast)A0, whereAslow
and Afast are the amplitudes of the slow and fast inactivating
current components, respectively, and slow and fast are the
decay time constants ofAslow andAfast, respectively. A standard
two-pulse protocol was used to generate the voltage depen-
dence of steady-state inactivation curves; from a HP of 120
mV, cells were stepped to 1-s conditioning potentials varying
from 120 to 50 mV (prepulse) in 5-mV increments, fol-
lowedby 20-ms test pulses to20mV (5-s interpulse duration).
Current amplitudes measured at each test pulse were normal-
ized to the maximal current amplitude (Imax), and the steady-
state inactivation curves were fitted with the Boltzmann equa-
tion I  Imax/(1  exp ((Vm  V1⁄2)/k)), in which V1⁄2 is the
membrane potential for half-inactivation, and k is the slope
factor. Recovery from inactivation was assessed using a three-
pulse protocol (5-s interpulse duration) with a test pulse (at
20mV) at variable times (from 1 to 200ms at120mV) after
a 1-s conditioning pulse to20 mV (from a HP of120 mV).
The time course of recovery from inactivation was analyzed by
fitting the current amplitudes measured at each test pulse nor-
malized to the current amplitudes measured during each con-
ditioning pulse with the single exponential function I(t) A
(1 exp(t/rec)).
In experiments aimed at recording the TTX-sensitive late
Na current, cells were bathed in external (full Na) solution
containing (in mM) the following: NaCl 140, CsCl 5, HEPES 10,
glucose 5, CaCl2 1, MgCl2 2 (pH 7.4 with CsOH,300 mosM).
Repetitive 350-ms test pulses to 20 mV from a HP of 120
mV (5-s interpulse duration) were applied to cells superfused
locally with external (full Na) solutions supplemented with 20
mMmannitol, in the absence and in the presence of 30MTTX
(Tocris Bioscience). Only cells exhibiting peak current ampli-
tudes of 
4000 pA were used (those with peak current of
4000 pAdid not showmeasurable lateNa current), and cells
with difference in leak current amplitudes before and after TTX
application of
2 pA at20mV (calculated from leak currents
at120 mV) were excluded from analyses. TTX-sensitive cur-
rents from individual cells were determined by off-line digital
subtraction of average leak-subtracted currents obtained from
five recordings in the absence and in the presence of TTX after
achieving steady state. The amplitude of TTX-sensitive late
Na current was defined as the steady-state current amplitude
(A0) obtained by fitting the inactivation decay of macroscopic
TTX-sensitive current with the double exponential function
I(t)  Aslow  exp(t/slow)  Afast  exp(t/fast)  A0. For
each cell, the TTX-sensitive late Na current amplitude was
normalized to the Cm, and expressed as TTX-sensitive late
Na current density (in pA/pF).
Statistical analyses
Results are expressed as means S.E. Data were first tested
for normality using the D’Agostino and Pearson normality test.
Depending on the results of normality tests, statistical analyses
were then performed using the Mann-Whitney nonparametric
test, the one-way ANOVA followed by the Dunnett’s post hoc
test, or the Kruskal-Wallis one-way ANOVA followed by the
Dunn’s post hoc test as indicated in the figures and tables. All of
these analyses, the Tukey whisker analysis and the plots, were
performed using Prism (GraphPad software).
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Legend of Supplementary Figures 1. Representative high- or low-resolution tandem mass (MS2) 
spectra of singly, doubly or triply phosphorylated NaV1.5 tryptic peptides (listed in Table 1) 
demonstrating the phosphorylation of the serines 36, 39, 42 and/or the threonine 38 (pS36, pT38, pS39 
and/or pS42), the serines 457 (pS457), 460 (pS460), 483 (pS483), 484 (pS484), 497 (pS497), 499 
(pS499), 510 (pS510), 516 (pS516), 524 and/or 525 (pS524 and/or pS525), 539 (pS539), 571 (pS571), 
664 (pS664), 1012 (pS1012), 1888 (pS1888), 1937 (pS1937), 1938 (pS1938) and 1989 (pS1989), and 
the threonine 486 (pT486). The small insets show representative spectra of precursor ions (MS1 
spectra) that were used and fragmented to produce the MS2 spectra. The presence of the y- 
(highlighted in blue) and b- (in red) ion series describing the amino acid sequences, of the loss of 
phosphoric acid peaks (in green) as well as of the unphosphorylated and phosphorylated site-
discriminating (or supporting) ions unambiguously supported the assignments of the indicated 
phosphorylation site(s). The mass errors of parent ions (in ppm) and the Mascot Ion scores for each 
phosphopeptide are indicated at the top of each page. The charge state confirmations and the 
percentage of maximum intensities of site-discriminating ions are presented in Table 1, and the 
complete list of assigned ions is given in Supplementary Tables 4. 
 
Legend of Supplementary Tables 1, 2 and 3. Lists of identified peptides and proteins using the 
LTQ-Orbitrap XL (1), the LTQ-Orbitrap Elite (2) and the TripleTOF 5600 Plus (3) mass 
spectrometers. In each peptide data table (spreadsheets #1), the MASCOT ion score, the observed m/z 
and the calculated mass error (in ppm) are shown. In the protein tables (spreadsheets #2), the percent 
protein identification probability, the exclusive unique peptide and spectrum counts, the exclusive 
spectrum count and the percent amino acid sequence coverage are indicated. 
 
Legend of Supplementary Tables 4. The calculated mass errors (in ppm) and charge state 
confirmations (presence or absence of the 13C isotopic peak) for all supporting b- and y-ions (as well 
as for the loss of phosphoric acid peaks) observed in the high- or low-resolution MS2 spectra of each 
annotated NaV1.5 phosphopeptide (listed in Table 1 and represented in Supplementary Figures 1) are 
summarized. Spreadsheet titles indicate the m/z values of the presented phosphopeptides. 
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Nerbonne_029_2506_291_10_ #7340 (LTQ-Orbitrap Elite, high-resolution MS2)
GSATSQESREGLPEEEAPRPQLDLQASK (aa 35-62), m/z = 773.365, +4, 1P (pS36, pT38, pS39 and/or pS42)
Mass error: -0.29 ppm, Mascot Ion score: 19.3
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Nerbonne_029_2506_263_10_ #8909.2 (TripleTOF 5600, high-resolution MS2)
GVDTV(pS)RS(pS)LEMSPLAPVTNHER (aa 452-474), m/z = 661.305, +4, 2P (pS457 + pS460)
Mass error: 9.8 ppm, Mascot Ion score: 81.9
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Nerbonne_029_2506_291_11_ #8882 (LTQ-Orbitrap Elite, high-resolution MS2)
GVDTVSRS(pS)LEMSPLAPVTNHER (aa 452-474), m/z = 854.739, +3, 1P (pS460)
Mass error: -0.48 ppm, Mascot Ion score: 87.3
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Nerbonne_029_2506_263_11_ #6250.4 (TripleTOF 5600, high-resolution MS2)
RL(pS)(pS)GTEDGGDDRLPK (aa 481-496), m/z = 621.596, +3, 2P (pS483 + pS484)
Mass error: 2.7 ppm, Mascot Ion score: 75.7
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Nerbonne_029_2506_263_11_ #5919.7 (TripleTOF 5600, high-resolution MS2)
KRLSSGTEDGGDDRLPK (aa 480-496), m/z = 664.294, +3, 2P (pS483 or pS484 + pT486)
Mass error: 3.3 ppm, Mascot Ion score: 41.1
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Nerbonne_029_2506_263_10_ #6268.10 (TripleTOF 5600, high-resolution MS2)
RL(pS)(pS)G(pT)EDGGDDRLPK (aa 481-496), m/z = 648.251, +3, 3P (pS483 + pS484 + pT486)
Mass error: 1.5 ppm, Mascot Ion score: 28.5
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Nerbonne_029_2506_263_11_ #5998.6 (TripleTOF 5600, high-resolution MS2)
LS(pS)GTEDGGDDRLPK (aa 482-496), m/z = 542.906, +3, 1P (pS484)
Mass error: 2.0 ppm, Mascot Ion score: 93.0
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Nerbonne_029_2506_263_10_ #6115.6 (TripleTOF 5600, high-resolution MS2)
LSSGTEDGGDDRLPK(pS)DSEDGPR (aa 482-504), m/z = 618.266, +4, 1P (pS497)
Mass error: 2.5 ppm, Mascot Ion score: 55.6
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Nerbonne_029_2506_011_05_ #992 (LTQ-Orbitrap XL, low-resolution MS2)
SD(pS)EDGPR (aa 497-504), m/z = 471.665, +2, 1P (pS499)
Mass error: 3.6 ppm, Mascot Ion score: 38.2
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Nerbonne_029_2506_291_10_ #8260 (LTQ-Orbitrap Elite, high-resolution MS2)
ALNQL(pS)LTHGLSR (aa 505-517), m/z = 745.380, +2, 1P (pS510)
Mass error: -0.55 ppm, Mascot Ion score: 69.7
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Nerbonne_029_2506_291_10_ #8262 (LTQ-Orbitrap Elite, high-resolution MS2)
ALNQL(pS)LTHGLSR (aa 505-517), m/z = 497.256, +3, 1P (pS510)
Mass error: 0.46 ppm, Mascot Ion score: 52.2
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Nerbonne_029_2506_263_10_ #8498.5 (TripleTOF 5600, high-resolution MS2)
ALNQLSLTHGL(pS)R (aa 505-517), m/z = 497.260, +3, 1P (pS516)
Mass error: 7.5 ppm, Mascot Ion score: 52.7
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Nerbonne_029_2506_291_10_ #8806 (LTQ-Orbitrap Elite, high-resolution MS2)
SSRGSIFTFR (aa 524-533), m/z = 619.290, +2, 1P (pS524 and/or pS525)
Mass error: 0.10 ppm, Mascot Ion score: 27.1
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Nerbonne_029_2506_263_10_ #6370.2 (TripleTOF 5600, high-resolution MS2)
DQG(pS)EADFADDENSTAGESESHR (aa 536-558), m/z = 845.312, +3, 1P (pS539)
Mass error: -0.88 ppm, Mascot Ion score: 141.5
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Nerbonne_029_2506_263_10_ #7326.3 (TripleTOF 5600, high-resolution MS2)
RP(pS)TQGQPGFGTSAPGHVLNGK (aa 569-590), m/z = 569.029, +4, 1P (pS571)
Mass error: 5.4 ppm, Mascot Ion score: 74.5
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Nerbonne_029_2506_011_01_ #9337 (LTQ-Orbitrap XL, low-resolution MS2)
AL(pS)AVSVLTSALEELEESHRK (aa 662-682), m/z = 783.731, +3, 1P (pS664)
Mass error: 3.9 ppm, Mascot Ion score: 50.1
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Nerbonne_029_2506_263_10_ #8081.5 (TripleTOF 5600, high-resolution MS2)
KPAALATHSQLPSC(+57)IAAPR(pS)PPPPEVEK (aa 993-1020), m/z = 758.148, +4, 1P (pS1012)
Mass error: 13 ppm, Mascot Ion score: 100.3
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Nerbonne_029_2506_263_10_from 208.625 to 208.683 min (TripleTOF 5600, high-resolution MS2)
AANP(pS)KISYEPITTTLR (aa 1884-1900), m/z = 647.994, +3, 1P (pS1888)
Mass error: 0.3 ppm
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Nerbonne_029_2506_263_10_ #6296.8 (TripleTOF 5600, high-resolution MS2)
Q(-17)QAGSSGLSDEDAPER (aa 1933-1948), m/z = 855.334, +2, 1P (pS1937 and/or pS1938)
Mass error: -3.8 ppm, Mascot Ion score: 106.9
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Nerbonne_029_2506_263_10_ from 112.322 to 112.453 (TripleTOF 5600, high-resolution MS2)
QAG(pS)(pS)GLSDEDAPER (aa 1934-1948), m/z = 560.211, +3, 2P (pS1937 and pS1938)
Mass error: -11.4 ppm
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Nerbonne_029_2506_263_10_ #6165.3 (TripleTOF 5600, high-resolution MS2)
AT(pS)DNLPVR (aa 1987-1995), m/z = 526.742, +2, 1P (pS1989)
Mass error: 0.41 ppm, Mascot Ion score: 39.2
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